KIT and lung cancer: The current study demonstrated the efficacy of FA-mExo siRNA-c-kit in overcoming gefitinib resistance both in vitro and in vivo, primarily by attenuating stemness features, including the reversal of EMT and reduction of ABCG2 expression levels in gefitinib-resistant lung cancer cells.